Background: Tumor volumes of more than 100 ml and the presence of primary metastases have been identified as determinants of poor prognosis in patients with Ewing tumors. We sought to assess the prevalence of critical tumor size and primary metastases in a large national sample of patients at the time of first diagnosis and to identify factors that are associated with their occurrence.
Summary
Background: Tumor volumes of more than 100 ml and the presence of primary metastases have been identified as determinants of poor prognosis in patients with Ewing tumors. We sought to assess the prevalence of critical tumor size and primary metastases in a large national sample of patients at the time of first diagnosis and to identify factors that are associated with their occurrence.
Patients • The present report is based on data of 945 German patients who were enrolled into the (EI)CESS therapy studies between 1980 and 1997. It is assumed that registration of German patients with Ewing tumors under the age of 15 years was almost complete since around 1985. Diagnoses of primary tumors were ascertained exclusively by biopsies. Analyses were restricted to patients with Ewing tumors of bone due to the few occurrences in soft tissues.
Methods: Tumor volume data as assessed by radiography, computed tomography or nuclear magnetic imaging were available for 821 patients. The diagnosis of primary metastases was based on thoracic computed tomography or on whole body bone scans in 936 patients. Suspicious lesions had to be confirmed by bone marrow biopsies. We explored how year of first diagnosis, age at first diagnosis, sex, histological subtype and site of the primary tumor related to tumor size and presence of metastases by univariate and multivariate statistical techniques.
Results: Sixty-eight percent of the patients (n = 559) had a volume above 100 ml with smaller tumors being more common in childhood than in late adolescence and early adulthood. Extensive volumes were observed in almost 90% of the tumors located in femur and pelvis while they were less common in other sites (P < 0.001). On average, 26% of all patients presented with clinically apparent primary metastases. The detection rate of metastases was markedly higher in patients diagnosed after 1991 (P < 0.001). Primary metastases were also significantly more common for tumors originating in the pelvis and for peripheral neuroectodermal tumors (PNET; P < 0.01). Tumors greater than 100 ml were positively associated with metastatic disease (P < 0.001). Multivariate analyses, which included simultaneously all univariate predictors in a logistic regression model, indicated that most of the observed associations were essentially unconfounded. The adjusted odds ratios (OR) for the presence of tumor volumes ^ 100 ml were OR = 1.5 per age rise of 10 years, and OR = 5.8 for pelvis and OR = 7.1 for femur as primary tumor site (all P < 0.001). The presence of metastases was significantly associated with the year of diagnosis (OR = 1.9, after 1991 vs. before 1986), pelvis as site of the primary tumor (OR = 1.8), a PNET (OR = 1.5), and tumor size $> 100 ml (OR = 1.6).
Introduction
Ewing tumors of bone, that is, Ewing's sarcoma and malignant peripheral neuroectodermal tumors (PNET) [1] [2] [3] [4] , are the second most common primary osseous malignancies in childhood and adolescence [5] [6] [7] [8] [9] . In addition, a considerable number of cases occur up into early adulthood, in particular among men [6, 10] . Major determinants of a poor prognosis of these tumors are volumes above 100 ml [11, 12] and the presence of primary metastases at diagnosis [13, 14] . Metastases are mostly found in the lung, and in bone and bone marrow [13] .
The frequency with which unselected patients diagnosed for the first time with a Ewing tumor present with extensive tumor volumes has not been firmly established. Likewise, the percentage of primary metastases among these patients has rarely been systematically investigated. The considerable variability between the reported series of selected patient groups ranged from 45%-70% for tumor volumes ^ 100 ml [11, 15, 16] and indicate an average proportion of about 20%-25% of patients who present with primary metastatic disease [13, 14, 17] .
We report here the findings for all German patients registered in the central database of multi-centre therapy studies carried out in Ewing tumor patients between 1980 and 1997, the (EI)CESS studies [18] [19] [20] . Of note, patients in this database were largely unselected for clinical characteristics and, therefore, much less constrained by restrictive inclusion criteria than most of the patient groups commonly presented in clinical reports.
In this large sample of patients, we investigated the prevalence of tumor volumes over 100 ml and of primary metastases at the time of first presentation, and explored how this related to the year of diagnosis, age and sex of the patients, the histological subtypes of Ewing tumors, and to the site of the primary tumor. [10] . The degree of the completeness of registration, however, is not known for this age range. The standardized annual incidence rate before age 15 years in this patient population has been estimated as 3.2 per million [10] . Diagnosis of the primary Ewing tumor in all patients was ascertained by biopsy Histological subtypes were categorized as typical Ewing's sarcoma (EWS), that is, barely differentiated osseous tumor with small, round, blue cells and no expression of neuronal markers [23] , as 'atypical Ewing's sarcoma' with only one neuronal marker or larger cell types [24] , and as malignant 'peripheral neuroectodermal tumors (PNET)' with at least two different neuronal markers and/or Homer-Wright rosettes by electron microscopy [1, 3, 25] . Only Ewing tumors of bone were available for the present analyses as, in Germany, patients with soft tissue EWS or PNET were in the past registered with a separate soft tissue sarcoma register.
Tumor volumes were assessed by proper imaging of the primary tumor sites as previously described [11, 15, 16] . In brief, the work-up included radiography of the tumor in two planes and exact evaluation of tumor shape and size by computed tomography (CT). If available, volume evaluation was complemented with nuclear magnetic response imaging (MRI). Maximal tumor extensions were determined and tumor size was calculated according to formulae adapted to ellipsoidal or cylindrical tumor configuration [11. 15. 16] . For the present investigation tumor volume was dichotomized as lower or greater than 100 ml. This value had previously been identified as valid for a prognostic partition of patient groups [11, 15] and was used as stratification criterion for patient randomisations in EICESS 92. Information on tumor volume was available for 821 patients or 87% of the study population.
The diagnosis of primary metastases was based on thoracic CT, or on whole body technetium bone scans with additional MRI and/or CT scans to define soft tissue involvement. Biopsy of at least one suspected lesion was mandatory 1 in cases of doubt about the nature of suspicious lesions. Diffuse bone marrow involvement was to be histologically confirmed by biopsies from bone marrow sites distant from the primary tumor. Tumor cells in peripheral blood or bone marrow only detectable by PCR based techniques were not considered indicative of disseminated disease. Information on the presence of primary metastases was available for 936 of the 945 patients.
Factors potentially associated with tumor size and primary metastases were chosen from the joint database of the (EI)CESS studies. They had been recorded in all patients by standardized study protocols. All factors were categorized and encompassed the year of diagnosis (before 1986, 1986-1991, after 1991) , age at first diagnosis by five-years groups, sex, the histological subtypes (EWS, atypical EWS, and PNET), and the sites of the primary tumors (pelvis, axial skeleton, femur, other extremity bones). A description of frequencies and distributions of these factors in the (EI)CESS patients has been published recently [10] .
Frequencies are given as percentages per category (relative frequencies), associations are assessed by stratified analyses and their statistical significance by chi-square-tests. Multivariate logistic regression analyses were employed to identify independent influences of single factors. The strength of these associations are expressed as ratios of the odds for having a tumor volume larger than 100 ml or primary metastases and their respective 95% confidence intervals.
Results

Univariate associations
The frequency of tumor volumes greater than 100 ml increased significantly with age (P < 0.001). Table 1 demonstrates that already in the very young patients more than one third presented with prognostically unfavorable tumor sizes. Above 15 years of age, three out of four Ewing tumor patients exhibited a volume greater than 100 ml. There was no discernible difference in tumor sizes between the sexes.
Contrasting with the age-dependency of tumor size, the occurrence of primary metastatic disease seemed essentially independent of age. Between 16% and 31% of the (EI)CESS patients presented with primary metastases ( Table 1 ). The occurrence of metastases was almost identical in patients of both sexes.
The percentage of patients with tumor volumes above 100 ml remained widely constant over the diagnostic periods and amounted to 63.5% before 1986, to 69.6% between 1986 and 1991, and to 68.8% after 1991. On the other hand, the year of diagnosis had a substantial impact on the detection rate of primary metastases < 1986 1986-1991 >1991
Year of diagnosis Figure I . Relative frequency (in %) of the presence of primary metastases, by diagnostic periods.
Primary tumor site
Axial skeleton • Tumor volume >s 100 ml a Primary metastases Figure 2 . Relative frequencies (in %) of tumor volumes > 100 ml and presence of primary metastases. by site of the primary tumor.
(P < 0.001). Detection was particularly high (33.5%) in patients seen after 1991 (Figure 1) .
The site of the primary tumor was also associated with its volume (P < 0.001). Especially in femur and pelvis, almost all tumors had volumes of more than 100 ml (Figure 2 ). The association of the site of the primary tumor with the presence of metastases was less pronounced. Nevertheless, metastases were significantly (P < 0.01) more common if tumors originated in the pelvis (Figure 2) .
The histological subtypes showed no clear relation with tumor size. Small tumors were, however, more common in patients with atypical EWS (42% of 87 patients) as compared to typical EWS (30% of 544 patients) and PNET (33% of 190 patients), respectively. Due to the low numbers of patients in the group with atypical EWS these differences did not reach statistical significance. On the other hand, Figure 3 demonstrates that patients with PNET presented more often with primary metastases than did patients with EWS or atypical EWS {P < 0.05). Finally, primary metastases were more common when the primary tumor was bigger. Of 555 patients with tumor volumes above 100 ml, 159 or 28.6% presented with metastases as compared to 18% of the 261 patients with smaller tumor size (P < 0.01). 
Multivariate analyses
In a concluding step of our analyses, we simultaneously included all factors that were univariately associated with tumor volumes above 100 ml or with the presence of primary metastases in logistic regression models to identify their independent contributions. The results of these multivariate analyses are given in Table 2 . The likelihood of having a tumor with a volume of greater than 100 ml increased by 50% with every 10 years of age (P = 0.004). Location of the primary tumor in pelvis or femur had a dramatic impact and raised the chance of having volumes above 100 ml five-to seven-fold (P < 0.001). Other factors showed only weak relations to tumor size.
The presence of primary metastases was independently associated to various factors. Patients with PNET had a 50% higher risk of metastatic disease that was independent of all other explanatory variables considered (P = 0.036). Detection rates were almost doubled in the period after 1991 as compared to before 1986 (P = 0.007) and this difference was not accounted for by different patient characteristics such as age, tumor size or a predominance of men. Metastases were also more common (OR = 1.8, P -0.002) for Ewing tumors in the pelvis as compared to other bone sites. Finally, larger tumors independently conferred a 60% higher risk of metastases than smaller ones {P = 0.019).
Discussion
In patients with Ewing tumors, only extent of disease at diagnosis discriminates between groups with marked differences in outcome [26] . We report here that in a large sample of essentially unselected patients diagnosed with Ewing tumors, 68.1% presented with tumors that were larger than 100 ml and 26% had primary metastases. These high prevalences suggest that tumors of the Ewing family are commonly diagnosed in clinically advanced stages where the disease has already surpassed critical limits of local growth or even has disseminated into the lung or other bone and bone marrow.
Rates of primary metastases that were similar to the ones found in our patients have been reported before from series of clinically selected patients [13, 17] . It should be noted, however, that in our study the rate of detected metastases rose significantly from 19% in cases diagnosed before 1986 to 34% after 1991. This sizable time trend remained significant after adjustment for potentially confounding factors with an odds ratio of 1.9. We think it is likely that the recent progress in imaging techniques and their increasing availability attributed substantially to the apparent increment in detection rates. Consequently, underdetection will have affected the overall prevalence estimates of our study and the true prevalence of primary metastases in unselected patients is probably close to approximately 35%. This estimate excludes still the proportion of patients with minute metastatic disease as yet invisible to traditional methods of detection [26] .
For a long time, tumor volumes above 100 ml have been associated with worse outcomes [11, 13, 14, 20, 26, 27] . A new report from the CESS 86 indicates now that this may no longer be appropriate. Ahrens et al. found no prognostic differences between patients having tumor volumes between 100 to 200 ml and those having smaller volumes [15] . Event-free survival time was halved, however, when tumor volumes exceeded 200 ml. The authors propose a shift of the prognostically critical limit of tumor volume to 200 ml. In our dataset, only a dichotomized clinical information was recorded for a considerable number of cases indicating whether tumors were below or above the traditional 100 ml cutoff. In 663 patients with available detailed volume measurements we observed a proportion of 39.7% presenting with tumors larger than 200 ml. As the associations with cofactors and, in particular, with metastatic disease did not differ qualitatively between tumor volumes ^ 100 ml and ^200 ml we report here mainly the results for the entire group using the traditional 100 ml limit.
Whatever definition of tumor volume is used, there remains the disconcerting observation that a major part of patients present with extensive localized disease. On one hand, tumor size was positively related to age and for a 10-years increment of age patients had a 50% increased risk of larger tumors. On the other hand, the site of the primary tumor had an even greater and very distinct impact on volume. Risks of larger tumor volumes were raised in Ewing tumors originating from pelvis or femur five-to seven-fold compared to that of patients with tumors in the other sites. These findings are suggestive of a predominant role of bone size which appears to facilitate and enhance asymptomatic tumor growth. If bone has grown to a certain size and if the anatomical configuration provides sufficient space for tumor growth the appearance of clinical signs is retarded and it seems difficult to conceive of any preventive strategies to improve earlier detection of Ewing tumors. Perhaps awareness can be raised among general physicians that, despite their relative rarity, Ewing tumors must be considered early as a differential diagnosis particularly in young adults with unspecific symptoms in the typically predisposed sites.
Our study confirms also previous reports on a close relationship between local extension of the primary tumor and the presence of metastases [13, 14, 27, 28] . Multivariate analyses in our sample of patients demonstrate that pelvic lesions confer an increased risk for metastatic disease in the order of 80% that appears to be independent of tumor volume, year of diagnosis or histology. Pelvic site of the primary tumor has been identified before as another major determinant of unfavorable outcome in Ewing tumors [13, 27] . Our analyses indicate that the worse prognosis of pelvic lesions may be conceived as a combination of adverse impacts on the occurrence of metastases. This combined effect originates from the larger tumor sizes in this location and an additional effect that appears specific to the pelvic site and that was not explained by the variables considered in our statistical analyses. Our study falls short of providing any further clues as to what may constitute this specific feature of pelvic lesions.
The role of different histological subtypes of the Ewing family of tumors as it relates to prognosis and outcome has been debated controversially [1] [2] [3] [4] 29] . Patients in our sample with a PNET presented significantly more often with primary metastases. Like the metastases, PNET were more frequently detected in patients who were diagnosed after 1986. Their primary sites were the central skeleton [10] . When we considered all the potentially confounding factors in our multivariate analyses the adjusted odds ratio for the presence of primary metastases remained still at OR -1.5 (P < 0.036). It may be suggested that this increased tendency to dissemination could adversely affect the prognosis of patients with PNET. However, the cross-sectional nature of this study does not allow any firm conclusions to this end.
There are few more limitations to this study. In particular, tumor volumes were not available for all patients. This may theoretically compromise our claim that this patient group is essentially unselected. However, we did not find any indication that the 123 patients for whom no tumor volumes were recorded in the database differed systematically from the 821 patients with such data. We therefore assume that the latter represent validly the entire group and that, in particular, the multivariate regression models for the presence of primary metastases -which are based exclusively on the 821 patients providing data for tumor volumeproduced meaningful results.
In conclusion, we find that the prevalence of established factors for an unfavorable prognosis is disturbingly high among patients diagnosed with Ewing tumors. We identify age and, in particular, pelvic and femoral site as the major determinants of local tumor extension. Occurrence of primary metastases is independently related to tumor size, pelvic site, and PNET.
